The Effect of Amiloride and Spironolactone in Healthy Persons
NCT ID: NCT00857909
Last Updated: 2011-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2009-01-31
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables
NCT01195805
The Effect of Amiloride and Spironolactone in Patients With Hypertension
NCT01388088
Comparison of Single and Combination Diuretics in Low-Renin Hypertension
NCT02351973
Double Blind Crossover Comparison of Diuretics in the Young
NCT00429897
Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN
NCT03683069
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Renal function (GFR, u-AQP2, u-ENaCĪ², u-cAMP, u-PGE2, CH20, FENa, FEK),
2. Pulsbewave velocity, augmentation index and central blood pressure,
3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and
4. Ambulatory blood pressure
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Randomisation 1
Amiloride 5 mg twice daily for 28 days, later compared with spironolactone and placebo
Amiloride
1 tablet twice a day
Placebo and spironolactone
5mg twice daily
Randomisation 2
Spironolactone 25 mg twice daily, to be compared with placebo and amiloride
Spironolactone
1 tablet twice a day
Spironolactone
25mg twice daily
Placebo
calcium tablet
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amiloride
1 tablet twice a day
Spironolactone
1 tablet twice a day
Placebo
Placebo
Placebo and spironolactone
5mg twice daily
Spironolactone
25mg twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-smokers
Exclusion Criteria
* Under medical treatment
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regional Hospital Holstebro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medical Research Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erling B Pedersen, Prof
Role: PRINCIPAL_INVESTIGATOR
Regional Hospital Holstebro
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Research
Holstebro, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MED.RES:HOS:SKM.02.2009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.